Locally Advanced or Metastatic NSCLC Clinical Trial
Official title:
An Open-lable, Two- Period, Single-sequence, Self-controlled Study to Evaluate the Effect of Oral Rifampicin or Itraconazole on the Pharmacokinetics of ASK120067 Tablets
To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of ASK120067 and its metabolite CCB4580030 in healthy subjects. To evaluate the safety of ASK120067 tablets or combination with rifampicin capsules or itraconazole capsules in healthy subjects.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03037086 -
Asia PDL1 Study Among NSCLC Patients
|
N/A | |
Recruiting |
NCT05662670 -
A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03274479 -
PBF-1129 in Patients With NSCLC
|
Phase 1 | |
Recruiting |
NCT03502850 -
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05990127 -
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03969823 -
Whole Genomic Landscape of Advanced EGFR-mutant NSCLC
|
N/A | |
Completed |
NCT04207775 -
Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
|
||
Not yet recruiting |
NCT06461156 -
A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
|
Phase 1 | |
Active, not recruiting |
NCT04143607 -
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Completed |
NCT03414814 -
Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
|
Phase 2 | |
Completed |
NCT04360915 -
Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects
|
Phase 1 |